{"id":"https://openalex.org/W59659877","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4517","title":"Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC)","display_name":"Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC)","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W59659877","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4517","mag":"59659877"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.4517","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4517","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.4517","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028789952","display_name":"Marc Dror Michaelson","orcid":"https://orcid.org/0000-0001-9249-6338","observed_orcids":["https://orcid.org/0000-0001-9249-6338"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"M. D. Michaelson","raw_affiliation_strings":["MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210116403","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024482335","display_name":"Timothy D. Gilligan","orcid":"https://orcid.org/0000-0003-2308-9303","observed_orcids":["https://orcid.org/0000-0003-2308-9303"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"T. Gilligan","raw_affiliation_strings":["MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210116403","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078027978","display_name":"William K. Oh","orcid":"https://orcid.org/0000-0001-5113-8147","observed_orcids":["https://orcid.org/0000-0001-5113-8147"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"W. Oh","raw_affiliation_strings":["MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210116403","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056766924","display_name":"Philip W. Kantoff","orcid":"https://orcid.org/0000-0001-7275-0597","observed_orcids":["https://orcid.org/0000-0001-7275-0597"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"P. Kantoff","raw_affiliation_strings":["MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210116403","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025433789","display_name":"M. Taplin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"M.-E. Taplin","raw_affiliation_strings":["MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210116403","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075656335","display_name":"Miguel Angel Izquierdo","orcid":"https://orcid.org/0000-0002-3596-928X","observed_orcids":["https://orcid.org/0000-0002-3596-928X"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"M. A. Izquierdo","raw_affiliation_strings":["MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210116403","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112092767","display_name":"Larissa Cristina Barbosa Flores","orcid":"https://orcid.org/0009-0003-3345-8712","observed_orcids":["https://orcid.org/0009-0003-3345-8712"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"L. Flores","raw_affiliation_strings":["MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210116403","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089854184","display_name":"Mitchell Reed Smith","orcid":"https://orcid.org/0000-0003-1428-8765","observed_orcids":["https://orcid.org/0000-0003-1428-8765"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"M. R. Smith","raw_affiliation_strings":["MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210116403","https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"4517","last_page":"4517"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trabectedin","display_name":"trabectedin","score":0.996999979019165},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9020000100135803},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.9399999976158142},{"id":"https://openalex.org/keywords/docetaxel-refractory-disease","display_name":"docetaxel-refractory disease","score":0.8610000014305115},{"id":"https://openalex.org/keywords/psa-response","display_name":"PSA response","score":0.6669999957084656},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.6669999957084656},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7749999761581421}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9086451530456543},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.8451740741729736},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.6047313213348389},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5854469537734985},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5696992874145508},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.4701195955276489},{"id":"https://openalex.org/C2776235491","wikidata":"https://www.wikidata.org/wiki/Q9625","display_name":"Prostate","level":3,"score":0.4635874927043915},{"id":"https://openalex.org/C2780752271","wikidata":"https://www.wikidata.org/wiki/Q2637746","display_name":"Trabectedin","level":4,"score":0.4444847106933594},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.44226503372192383},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4196535348892212},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.41532883048057556},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.4130031168460846},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3760165572166443},{"id":"https://openalex.org/C2778256501","wikidata":"https://www.wikidata.org/wiki/Q223911","display_name":"Sarcoma","level":2,"score":0.2884448170661926},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.2245997190475464},{"id":"https://openalex.org/C2778629024","wikidata":"https://www.wikidata.org/wiki/Q720020","display_name":"Soft tissue sarcoma","level":3,"score":0.19375550746917725},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.1609143316745758}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.4517","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4517","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.4517","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2157092239","https://openalex.org/W2250001760","https://openalex.org/W1789332736","https://openalex.org/W2126644681","https://openalex.org/W2257092426","https://openalex.org/W2248930995","https://openalex.org/W2047010121","https://openalex.org/W2591515892","https://openalex.org/W1985172333","https://openalex.org/W2270872098"],"abstract_inverted_index":{"4517":[0],"Background:":[1],"Trabectedin":[2],"(T)":[3],"is":[4,142,288],"a":[5,37,74,95,198],"novel,":[6],"marine-derived":[7],"cytotoxic":[8],"agent":[9],"that":[10,57,286],"binds":[11],"to":[12,79,123,169,178,240],"the":[13,81,115,124,156,162,165,170,273],"minor":[14],"groove":[15],"of":[16,39,60,85,99,107,114,133,158,218,227],"DNA":[17],"and":[18,21,32,41,50,83,136,153,215,230,255,277,291],"induces":[19],"apoptosis":[20],"cell":[22,63,68],"cycle":[23],"arrest.":[24],"T":[25,61,86,287],"has":[26,42,150,167,208],"been":[27,151,176,194,265],"studied":[28],"in":[29,36,45,65,87,161,213,272,296,308],"phase":[30,75],"I":[31],"II":[33,76],"clinical":[34,43,77,294],"trials":[35,305],"variety":[38],"malignancies,":[40],"activity":[44,295],"soft":[46],"tissue":[47],"sarcoma,":[48],"breast":[49],"ovarian":[51],"carcinoma.":[52],"Preclinical":[53],"studies":[54,302],"have":[55,175,193,223,243,264,293],"demonstrated":[56],"low":[58],"concentrations":[59],"promote":[62],"death":[64],"prostate":[66],"cancer":[67],"lines.":[69],"Methods:":[70],"We":[71],"are":[72,92,306],"conducting":[73],"trial":[78,166],"determine":[80],"efficacy":[82],"safety":[84],"men":[88,174,196,222],"with":[89,94,128,184,197,204],"AIPC.":[90,300],"Men":[91],"treated":[93,183],"weekly,":[96],"three-hour":[97],"infusion":[98],"T,":[100],"at":[101],"0.580":[102],"mg/m2":[103],"for":[104,190],"3":[105,195,236],"out":[106],"4":[108,261],"weeks.":[109],"Inclusion":[110],"criteria":[111,121],"include":[112],"adenocarcinoma":[113],"prostate;":[116],"androgen-independent":[117],"disease":[118],"by":[119],"PSA":[120,125,200,214,225],"according":[122],"Working":[126],"Group":[127],"testosterone<50":[129],"ng/ml;":[130],"radiographic":[131],"evidence":[132],"metastatic":[134],"disease;":[135],"adequate":[137],"hepatic":[138],"function.":[139],"Target":[140],"accrual":[141],"33":[143],"subjects.":[144],"Results:":[145],"A":[146],"Simon\u2019s":[147],"two-stage":[148],"design":[149],"used,":[152],"based":[154],"on":[155],"number":[157],"responses":[159],"observed":[160],"initial":[163],"cohort,":[164],"proceeded":[168],"second":[171],"stage.":[172],"Twenty":[173],"enrolled":[177],"date,":[179],"including":[180,298,303],"8":[181],"previously":[182],"docetaxel-based":[185],"chemotherapy.":[186],"Of":[187],"those":[188],"evaluable":[189],"response,":[191],"there":[192],"confirmed":[199],"response.":[201],"One":[202],"man":[203],"symptomatic,":[205],"docetaxel-refractory":[206,299],"AIPC":[207],"manifested":[209],"an":[210],"86%":[211],"decrease":[212],"rapid":[216],"resolution":[217],"symptoms.":[219],"Two":[220],"other":[221],"had":[224],"declines":[226],"58.5%":[228],"(first-line)":[229],"79%":[231],"(second-line":[232],"following":[233],"docetaxel/estramustine).":[234],"Grade":[235],"adverse":[237,262],"events":[238,263],"related":[239],"study":[241],"drug":[242],"been:":[244],"elevated":[245],"GGT":[246],"(1":[247,250,253,257],"pt),":[248,251,254],"thrombocytopenia":[249],"fatigue":[252],"hyponatremia":[256],"pt).":[258],"No":[259],"grade":[260],"reported.":[266],"Conclusions:":[267],"Accrual":[268],"should":[269],"be":[270,281],"completed":[271],"next":[274],"few":[275],"months,":[276],"updated":[278],"results":[279,284],"will":[280],"presented.":[282],"Preliminary":[283],"suggest":[285],"well":[289],"tolerated":[290],"may":[292],"AIPC,":[297],"Additional":[301],"combination":[304],"warranted":[307],"this":[309],"patient":[310],"population.":[311],"Author":[312],"Disclosure":[313],"Employment":[314],"or":[315,318],"Leadership":[316],"Consultant":[317],"Advisory":[319],"Role":[320],"Stock":[321],"Ownership":[322],"Honoraria":[323],"Research":[324],"Funding":[325],"Expert":[326],"Testimony":[327],"Other":[328],"Remuneration":[329],"PharmaMar":[330],"SA":[331]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}